Andrew L. Concoff

Andrew Concoff, MD, FACR, CAQSM has served as Chief Innovation Officer since October 2022. Dr. Concoff is a board-certified rheumatologist with a range of experience across the healthcare ecosystem and spans the gap between the basic and clinical science of Rheumatology and the business side of drug development and healthcare delivery that orbits around it. Dr. Concoff joins Exagen from United Rheumatology, where his work as Executive Vice President, Chief Medical Officer enables him to create, model, and implement value-based programs with payors, quality improvement initiatives with pharmaceutical manufacturers, and other clinical care innovations with stakeholders across the musculoskeletal ecosystem. Dr. Concoff has 15 years of clinical experience and served as a clinical reviewer for the Institute for Clinical and Economic Review (ICER) cost effectiveness assessments of both targeted synthetic and biologic medications for rheumatoid arthritis. He received his B.A. in Psychobiology from UCLA and an M.D. from UTHealth before completing his residency in Internal Medicine and fellowship in Rheumatology at UCLA.